Clinical outcomes and alternative chemotherapy (CT) options in patients (pts) with de novo carboplatin (carbo)-resistant stage III or IV ovarian cancer (CA) based on the drug-induced apoptosis (MiCK) assay. Article

Burrell, Matthew O, Stany, Michael, Rutledge, James et al. (2013). Clinical outcomes and alternative chemotherapy (CT) options in patients (pts) with de novo carboplatin (carbo)-resistant stage III or IV ovarian cancer (CA) based on the drug-induced apoptosis (MiCK) assay. . JOURNAL OF CLINICAL ONCOLOGY, 31(15_suppl), e16525-e16525. 10.1200/jco.2013.31.15_suppl.e16525

cited authors

  • Burrell, Matthew O; Stany, Michael; Rutledge, James; Salom, Emery Manuel; Penalver, Manuel; Hallquist, Allan; Presant, Cary A

authors

publication date

  • May 20, 2013

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 5.1 Pharmaceuticals
  • 6.1 Pharmaceuticals
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Minority Health
  • Orphan Drug
  • Ovarian Cancer
  • Rare Diseases
  • Women's Health

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • e16525

end page

  • e16525

volume

  • 31

issue

  • 15_suppl